PLX
Price
$1.16
Change
-$0.05 (-4.13%)
Updated
May 2, 6:59 PM EST
6 days until earnings call
RARE
Price
$43.20
Change
-$0.10 (-0.23%)
Updated
May 2, 6:59 PM EST
Earnings call today
Ad is loading...

Analysis and predictions PLX vs RARE

Header iconPLX vs RARE Comparison
Open Charts PLX vs RAREBanner chart's image
Protalix BioTherapeutics
Price$1.16
Change-$0.05 (-4.13%)
Volume$56.88K
CapitalizationN/A
Ultragenyx Pharmaceutical
Price$43.20
Change-$0.10 (-0.23%)
Volume$489.86K
CapitalizationN/A
View a ticker or compare two or three
PLX vs RARE Comparison Chart

Loading...

PLXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RAREDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
PLX vs. RARE commentary
May 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLX is a Hold and RARE is a Hold.

COMPARISON
Comparison
May 02, 2024
Stock price -- (PLX: $1.21 vs. RARE: $43.30)
Brand notoriety: PLX and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PLX: 88% vs. RARE: 191%
Market capitalization -- PLX: $88.39M vs. RARE: $3.6B
PLX [@Biotechnology] is valued at $88.39M. RARE’s [@Biotechnology] market capitalization is $3.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $578.54B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLX’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • PLX’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, PLX is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLX’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • PLX’s TA Score: 5 bullish, 2 bearish.
  • RARE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PLX is a better buy in the short-term than RARE.

Price Growth

PLX (@Biotechnology) experienced а 0.00% price change this week, while RARE (@Biotechnology) price change was -2.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.13%. For the same industry, the average monthly price growth was -1.93%, and the average quarterly price growth was +1240.72%.

Reported Earning Dates

PLX is expected to report earnings on Aug 12, 2024.

RARE is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Biotechnology (+5.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for PLX with price predictions.
OPEN
A.I.dvisor published
a Summary for RARE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RARE($3.6B) has a higher market cap than PLX($88.4M). RARE YTD gains are higher at: -9.452 vs. PLX (-32.022).
PLXRAREPLX / RARE
Capitalization88.4M3.6B2%
EBITDAN/AN/A-
Gain YTD-32.022-9.452339%
P/E Ratio13.44N/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
PLX vs RARE: Fundamental Ratings
PLX
RARE
OUTLOOK RATING
1..100
1364
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1699
PRICE GROWTH RATING
1..100
8758
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PLX's Valuation (57) in the Servicestothe Health Industry industry is in the same range as RARE (72) in the Biotechnology industry. This means that PLX’s stock grew similarly to RARE’s over the last 12 months.

PLX's Profit vs Risk Rating (100) in the Servicestothe Health Industry industry is in the same range as RARE (100) in the Biotechnology industry. This means that PLX’s stock grew similarly to RARE’s over the last 12 months.

PLX's SMR Rating (16) in the Servicestothe Health Industry industry is significantly better than the same rating for RARE (99) in the Biotechnology industry. This means that PLX’s stock grew significantly faster than RARE’s over the last 12 months.

RARE's Price Growth Rating (58) in the Biotechnology industry is in the same range as PLX (87) in the Servicestothe Health Industry industry. This means that RARE’s stock grew similarly to PLX’s over the last 12 months.

PLX's P/E Growth Rating (98) in the Servicestothe Health Industry industry is in the same range as RARE (100) in the Biotechnology industry. This means that PLX’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PLXRARE
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 10 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
PLXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RAREDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BKGFY12.230.27
+2.26%
Berkeley Group Holdings Plc.
JAPAY13.490.08
+0.60%
Japan Tobacco
NVIVQ0.37N/A
N/A
InVivo Therapeutics Holdings Corp
BRWXF0.37N/A
N/A
BRUNSWICK EXPL INC
IPXHY14.63-0.34
-2.27%
Inpex Corp.

PLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PLX has been loosely correlated with NTLA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
+6.14%
NTLA - PLX
38%
Loosely correlated
+5.14%
CPRX - PLX
36%
Loosely correlated
+1.00%
CARM - PLX
35%
Loosely correlated
-1.23%
PRME - PLX
35%
Loosely correlated
+6.91%
RARE - PLX
35%
Loosely correlated
+1.79%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with AGIO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+1.79%
AGIO - RARE
51%
Loosely correlated
+3.52%
DNLI - RARE
50%
Loosely correlated
+4.60%
SRPT - RARE
47%
Loosely correlated
+3.24%
VCYT - RARE
46%
Loosely correlated
+2.86%
NTLA - RARE
46%
Loosely correlated
+5.14%
More